MedTrace Logo

Study of Tamibarotene in Patients With ADPKD

NCT06289998 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-04-04

No results posted yet for this study

Summary

Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease

Conditions

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

DRUG

Tamibarotene

Subjects are administrated to tamibarotene 4 mg in daily for 52 weeks.

DRUG

Placebo

Subjects are administrated to placebo in daily for 52 weeks.

Sponsors & Collaborators

  • Rege Nephro Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
26 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-22
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06289998 on ClinicalTrials.gov